继控股基准医疗后,康圣环球日前宣布完成对上海真固生物90%股权收购,构建泛肿瘤平台,补强“伴随诊断”核心环节。真固生物自2016年成立以来聚焦肿瘤伴随诊断,拥有SLIMamp®专利技术,业务涵盖院内精准诊断、生物标志物合作开发及精准医学检测。此次收购使康圣环球形成肿瘤早筛早诊(基准医疗)、伴随诊断(真固生物)、复发监测(旗下康圣真源MRD服务)三大核心环节业务闭环,有助于巩固其IVD领域地位。真固...
Source Link继控股基准医疗后,康圣环球日前宣布完成对上海真固生物90%股权收购,构建泛肿瘤平台,补强“伴随诊断”核心环节。真固生物自2016年成立以来聚焦肿瘤伴随诊断,拥有SLIMamp®专利技术,业务涵盖院内精准诊断、生物标志物合作开发及精准医学检测。此次收购使康圣环球形成肿瘤早筛早诊(基准医疗)、伴随诊断(真固生物)、复发监测(旗下康圣真源MRD服务)三大核心环节业务闭环,有助于巩固其IVD领域地位。真固...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.